Mcl-1 as a therapeutic target in acute myelogenous leukemia (AML)
Publication date: 2013 Source:Leukemia Research Reports, Volume 2, Issue 1 Author(s): Prithviraj Bose , Steven Grant The B-cell lymphoma-2 (Bcl-2) family of proteins regulates the intrinsic, or mitochondrial pathway of apoptosis, the final common mechanism of cell death in response to a variety of physiologic and pharmacologic signals, and plays a central role in AML pathogenesis, prognosis and responsiveness to chemotherapy. Traditionally thought to be an important survival factor for multiple myeloma cells, the anti-apoptotic Bcl-2 family protein myeloid cell leukemia-1 (Mcl-1) has recently been shown in preclinica...
Source: Leukemia Research Reports - October 12, 2014 Category: Hematology Source Type: research
Durable second complete remissions with oral melphalan in hypocellular Acute Myeloid Leukemia and Refractory Anemia with Excess Blast with normal karyotype relapsing after intensive chemotherapy
Publication date: 2013 Source:Leukemia Research Reports, Volume 2, Issue 1 Author(s): Annika M. Whittle , Sylvia Feyler , David T. Bowen We treated six patients who had relapsed after intensive chemotherapy, presenting initially with AML or RAEB, a hypocellular marrow and normal karyotype, and who were deemed unsuitable for re-induction with intensive chemotherapy, with low dose oral melphalan. Three of six patients achieved complete hematological response with no significant toxicity and with a duration of 12, 8 and 3+ months respectively. These three patients had received only two prior courses of chemotherapy eac...
Source: Leukemia Research Reports - October 12, 2014 Category: Hematology Source Type: research
Gelatinous transformation of bone marrow following the use of dasatinib in a patient with philadelphia chromosome-positive acute lymphoblastic leukemia
Publication date: 2013 Source:Leukemia Research Reports, Volume 2, Issue 1 Author(s): Sanjeev Kumar Sharma , Dharma Choudhary , Anil Handoo , Gaurav Kharya , Nitin Gupta , Punita Pavecha , Ritu Chadha (Source: Leukemia Research Reports)
Source: Leukemia Research Reports - October 12, 2014 Category: Hematology Source Type: research
Hemophagocytic lymphohistiocytosis masquerading as progressive chronic lymphocytic leukemia
We present the second known case of HLH associated Chronic Lymphocytic Leukemia (CLL) in the absence of infectious etiology and review the current literature. (Source: Leukemia Research Reports)
Source: Leukemia Research Reports - October 12, 2014 Category: Hematology Source Type: research
Somatic mutations of the CREBBP and EP300 genes affect response to histone deacetylase inhibition in malignant DLBCL clones
Publication date: 2013 Source:Leukemia Research Reports, Volume 2, Issue 1 Author(s): Christen Lykkegaard Andersen , Fazila Asmar , Tobias Klausen , Hans Hasselbalch , Kirsten Grønbæk Heterogeneous clinical responses to histone deacetylase inhibitors (HDACi) in diffuse large B-cell lymphoma (DLBCL) have prompted a need for evaluating the impact of mutations in the histone acetyl transferases (HAT) CREBBP and EP300 on HDACi treatment outcome. We identified four DLBCL cell lines; Toledo, with mutations in CREBBP and EP300, SUDHL-7 with mutation of CREBBP and wild-type (wt) EP300, RL with mutation of EP300 and wt C...
Source: Leukemia Research Reports - October 12, 2014 Category: Hematology Source Type: research
Haemoglobinopathia Ypsilanti – A rare, but important differential diagnosis to polycythaemia vera
We present a case of a mother and daughter who were initially diagnosed with polycythaemia vera and treated with venesectio. As JAK2 V6217F/exon 12 mutation analyses became available, these were performed and turned out negative. Haemoglobin electrophoresis was performed and the patients were found to have high oxygen affinity haemoglobin Ypsilanti. It is important and relevant to look for high oxygen affinity variants of haemoglobin when there is a family history of erythrocytosis, in young persons and when there is no apparent reason or clonal marker present. (Source: Leukemia Research Reports)
Source: Leukemia Research Reports - October 12, 2014 Category: Hematology Source Type: research
Rabbit antithymocyte globulin induces rapid expansion of effector memory CD8 T cells without accelerating acute graft versus host disease
Publication date: 2013 Source:Leukemia Research Reports, Volume 2, Issue 2 Author(s): Friedrich Wittenbecher , Kathrin Rieger , Mikalai Dziubianau , Anne Herholz , Angela Mensen , Igor Wolfgang Blau , Lutz Uharek , Bernd Dörken , Andreas Thiel , Il-Kang Na Rabbit antithymocyte globulin (Thymoglobulin®) is commonly used as graft-versus-host disease (GvHD) prophylaxis. Since we found similar total CD8 T cell numbers in patients with and without Thymoglobulin® therapy within the first six months after allogeneic hematopoietic stem cell transplantation, we have analyzed the reconstitution of the CD8 T cell com...
Source: Leukemia Research Reports - October 12, 2014 Category: Hematology Source Type: research
Differential cytogenetic profile in advanced chronic myeloid leukemia with sequential lymphoblastic and myeloblastic blast crisis
We report an exceptional case of CML as debut in lymphoblastic blast crisis and a subsequent progression in myeloblastic blast crisis with rare cytogenetic abnormalities. (Source: Leukemia Research Reports)
Source: Leukemia Research Reports - October 12, 2014 Category: Hematology Source Type: research
Standard and variant Philadelphia translocation in a CML patient with different sensitivity to imatinib therapy
We report the non simultaneous occurrence of two different types of Ph translocation in a CML patient: a t(9;22)(q34;q11) standard and a three-way variant t(9;11;22)(q34;p15;q11). Bone marrow cells with standard translocation did not have BCR/ABL kinase domain (KD) mutations and were sensitive to imatinib therapy. In contrast, bone marrow cells with the variant translocation showed two BCR/ABL KD mutations and were resistant to imatinib, thus inducing transformation to the blast phase and karyotype evolution. (Source: Leukemia Research Reports)
Source: Leukemia Research Reports - October 12, 2014 Category: Hematology Source Type: research
Lenalidomide monotherapy and in combination with cytarabine, daunorubicin and etoposide for high-risk myelodysplasia and acute myeloid leukaemia with chromosome 5 abnormalities
Publication date: 2013 Source:Leukemia Research Reports, Volume 2, Issue 2 Author(s): M. Dennis , D. Culligan , D. Karamitros , P. Vyas , P. Johnson , N.H. Russell , J. Cavenagh , A. Szubert , S. Hartley , J. Brown , D. Bowen Patients with high risk myelodysplasia (HR-MDS) and acute myeloid leukaemia (AML) with chromosomal changes involving deletion of the long arm of chromosome 5 (del5q), especially with complex karyotype, rarely have a durable response to combination chemotherapy. In the subgroup with monosomal karyotype there are no long term survivors (Fang et al., 2011) [1]. Recent experience indicates ...
Source: Leukemia Research Reports - October 12, 2014 Category: Hematology Source Type: research
Extramedullary blast crisis of chronic myelogenous leukemia as an initial presentation
Publication date: 2013 Source:Leukemia Research Reports, Volume 2, Issue 2 Author(s): Shokichi Tsukamoto , Satoshi Ota , Chikako Ohwada , Yusuke Takeda , Masahiro Takeuchi , Emiko Sakaida , Naomi Shimizu , Koutaro Yokote , Tohru Iseki , Chiaki Nakaseko Extramedullary blast crisis of chronic myelogenous leukemia (CML) is defined as the development of extramedullary disease caused by the infiltration of blasts regardless of proliferation of blasts in the bone marrow. The onset of extramedullary blast crisis in the newly diagnosed patients is known to be extremely rare. Here, we present a case of extramedullary ...
Source: Leukemia Research Reports - October 12, 2014 Category: Hematology Source Type: research
Prognostic impact of JAK2V617F mutation in myelodysplatic syndromes: A matched case control study
Publication date: 2013 Source:Leukemia Research Reports, Volume 2, Issue 2 Author(s): Benoit de Renzis , Veronique Mansat-De Mas , Eric Wattel , Odile Beyne-Rauzy , Laurent Knoops , Aurélie Cabrespine , Zahia Azgui , Lionel Ades , Jean-Jacques Kiladjian , Pierre Fenaux While in RARS-T, JAK2V617F mutation is common and associated with good prognosis, the clinical and prognostic impact of this mutation in other MDS is unknown. We collected data from 132 non-RARS-T MDS with known JAK2V617F mutation status. JAK2V617F mutation was significantly correlated with lower progression to AML (p<.0011) and better ...
Source: Leukemia Research Reports - October 12, 2014 Category: Hematology Source Type: research
Myeloproliferative neoplasms in five multiple sclerosis patients
We report five patients from a localized geographic area in Denmark with both MS and MPN; all the patients were diagnosed with MPNs in the years 2007–2012. We describe the patients' history and treatment. A potential link between MS and MPNs has not been previously recognized. This observation calls attention to potential environmental factors and/or previously unrecognized genetic factors predisposing these patients to both MS and MPNs. (Source: Leukemia Research Reports)
Source: Leukemia Research Reports - October 12, 2014 Category: Hematology Source Type: research
Leptin modification in chronic myeloid leukemia patients treated with imatinib: An emerging effect of targeted therapy.
This study suggests that imatinib therapy may result in leptin alteration. (Source: Leukemia Research Reports)
Source: Leukemia Research Reports - October 12, 2014 Category: Hematology Source Type: research
Lymphocyte recovery and infused CD34+ cells dose: Effect on the evolution after stem cell autotransplantation
Conclusions We have obtained a predictive model of lymphocyte recovery based recovery of CD34+i. (Source: Leukemia Research Reports)
Source: Leukemia Research Reports - October 12, 2014 Category: Hematology Source Type: research
